TY - JOUR T1 - Effective Heat Inactivation of SARS-CoV-2 JF - medRxiv DO - 10.1101/2020.04.29.20085498 SP - 2020.04.29.20085498 AU - Tony T. Wang AU - Christopher Z. Lien AU - Shufeng Liu AU - Prabhuanand Selvaraj Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20085498.abstract N2 - In this study, we aimed to evaluate the stability of SARS-CoV-2 under four different heat conditions (37, 42, 56, 60 °C) and report that the virus is stable at 37 °C for at least 24 hours. Heating at 56 °C for 30 minutes, however, effectively inactivated the virus while preserved the stability of viral RNA in both human sera and sputum samples. These findings provide critical information regarding the biology of the virus as well as a practical way to inactivate infectious virus that is potentially found in clinical specimens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded by the U.S. Food and Drug Administration.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available. ER -